Literature DB >> 32904147

Complete atrioventricular block and torsade de pointes due to dose-dense epirubicin and cyclophosphamide therapy.

Taiji Okada1, Miki Hyakudomi2, Kazuto Yamaguchi3, Nobuhide Watanabe3, Akihiro Endo3, Hiroyuki Yoshitomi4, Kazuaki Tanabe3.   

Abstract

The dose-dense epirubicin and cyclophosphamide (EC) therapy for breast cancer decreases the risk of cancer recurrence and death. However, epirubicin and cyclophosphamide also cause cardiotoxicity, and cardiomyopathy is the most well-known related adverse effect. A 58-year-old woman presented to our hospital with palpitations 2 weeks after her final dose-dense EC therapy for breast cancer. Holter electrocardiogram (ECG) showed transitory complete atrioventricular block (CAVB) and torsade de pointes. A 12-lead ECG showed QT prolongation in addition to CAVB. Patients receiving dose-dense EC therapy should be monitored more carefully with ECG due to their risk of fatal arrhythmias. © The Japan Society of Clinical Oncology 2020.

Entities:  

Keywords:  Breast cancer; Complete atrioventricular block; Dose-dense epirubicin and cyclophosphamide therapy; QT prolongation; Torsade de pointes

Year:  2020        PMID： 32904147      PMCID： PMC7450030          DOI： 10.1007/s13691-020-00427-1

Source DB:  PubMed          Journal:  Int Cancer Conf J        ISSN： 2192-3183


  13 in total

1.  Cardiac arrhythmias in patients with small cell lung cancer and cardiac disease before, during and after doxorubicin administration. An evaluation of acute cardiotoxicity by continuous 24-hour Holter monitoring.

Authors:  N K Raabe; L Storstein
Journal:  Acta Oncol       Date:  1991       Impact factor: 4.089

2.  Effect of Tailored Dose-Dense Chemotherapy vs Standard 3-Weekly Adjuvant Chemotherapy on Recurrence-Free Survival Among Women With High-Risk Early Breast Cancer: A Randomized Clinical Trial.

Authors:  Theodoros Foukakis; Gunter von Minckwitz; Nils-Olof Bengtsson; Yvonne Brandberg; Birgitta Wallberg; Tommy Fornander; Brigitte Mlineritsch; Sabine Schmatloch; Christian F Singer; Günther Steger; Daniel Egle; Eva Karlsson; Lena Carlsson; Sibylle Loibl; Michael Untch; Mats Hellström; Hemming Johansson; Harald Anderson; Per Malmström; Michael Gnant; Richard Greil; Volker Möbus; Jonas Bergh
Journal:  JAMA       Date:  2016-11-08       Impact factor: 56.272

3.  Significant impact of electrical storm on mortality in patients with structural heart disease and an implantable cardiac defibrillator.

Authors:  Takashi Noda; Takashi Kurita; Takashi Nitta; Yasutaka Chiba; Hiroshi Furushima; Naoki Matsumoto; Takeshi Toyoshima; Akihiko Shimizu; Hideo Mitamura; Ken Okumura; Tohru Ohe; Yoshifusa Aizawa
Journal:  Int J Cardiol       Date:  2018-03-15       Impact factor: 4.164

Review 4.  2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC).

Authors:  Jose Luis Zamorano; Patrizio Lancellotti; Daniel Rodriguez Muñoz; Victor Aboyans; Riccardo Asteggiano; Maurizio Galderisi; Gilbert Habib; Daniel J Lenihan; Gregory Y H Lip; Alexander R Lyon; Teresa Lopez Fernandez; Dania Mohty; Massimo F Piepoli; Juan Tamargo; Adam Torbicki; Thomas M Suter; Jose Luis Zamorano; Victor Aboyans; Stephan Achenbach; Stefan Agewall; Lina Badimon; Gonzalo Barón-Esquivias; Helmut Baumgartner; Jeroen J Bax; Héctor Bueno; Scipione Carerj; Veronica Dean; Çetin Erol; Donna Fitzsimons; Oliver Gaemperli; Paulus Kirchhof; Philippe Kolh; Patrizio Lancellotti; Gregory Y H Lip; Petros Nihoyannopoulos; Massimo F Piepoli; Piotr Ponikowski; Marco Roffi; Adam Torbicki; António Vaz Carneiro; Stephan Windecker
Journal:  Eur J Heart Fail       Date:  2016-08-27       Impact factor: 15.534

5.  Fluorouracil and dose-dense chemotherapy in adjuvant treatment of patients with early-stage breast cancer: an open-label, 2 × 2 factorial, randomised phase 3 trial.

Authors:  Lucia Del Mastro; Sabino De Placido; Paolo Bruzzi; Michele De Laurentiis; Corrado Boni; Giovanna Cavazzini; Antonio Durando; Anna Turletti; Cecilia Nisticò; Enrichetta Valle; Ornella Garrone; Fabio Puglisi; Filippo Montemurro; Sandro Barni; Andrea Ardizzoni; Teresa Gamucci; Giuseppe Colantuoni; Mario Giuliano; Adriano Gravina; Paola Papaldo; Claudia Bighin; Giancarlo Bisagni; Valeria Forestieri; Francesco Cognetti
Journal:  Lancet       Date:  2015-03-02       Impact factor: 79.321

6.  Notable effects of angiotensin II receptor blocker, valsartan, on acute cardiotoxic changes after standard chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisolone.

Authors:  Hirohisa Nakamae; Kei Tsumura; Yoshiki Terada; Takahiko Nakane; Mika Nakamae; Kensuke Ohta; Takahisa Yamane; Masayuki Hino
Journal:  Cancer       Date:  2005-12-01       Impact factor: 6.860

7.  Doxorubicin-induced ventricular arrhythmia treated by implantation of an automatic cardioverter-defibrillator.

Authors:  Tomasz Rudzinski; Michal Ciesielczyk; Wojciech Religa; Zbigniew Bednarkiewicz; Maria Krzeminska-Pakula
Journal:  Europace       Date:  2007-03-23       Impact factor: 5.214

Review 8.  Cancer therapy-induced cardiac toxicity in early breast cancer: addressing the unresolved issues.

Authors:  Michel G Khouri; Pamela S Douglas; John R Mackey; Miguel Martin; Jessica M Scott; Marielle Scherrer-Crosbie; Lee W Jones
Journal:  Circulation       Date:  2012-12-04       Impact factor: 29.690

Review 9.  Introducing a new entity: chemotherapy-induced arrhythmia.

Authors:  Maya Guglin; Mohsen Aljayeh; Saleemuddin Saiyad; Rias Ali; Anne B Curtis
Journal:  Europace       Date:  2009-10-03       Impact factor: 5.214

10.  Clinical Application of the Heart Rate Deceleration Capacity Test to Predict Epirubicin-induced Cardiotoxicity.

Authors:  Yan-ying Feng; Zhi-jun Yang
Journal:  J Cardiovasc Pharmacol       Date:  2015-10       Impact factor: 3.105
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.